## Biotechnologically Relevant Enzymes and Proteins

# Regioselective hydroxylation of cholecalciferol, cholesterol and other sterol derivatives by steroid C25 dehydrogenase

**J. Staro≈Ñ¬π¬≤, A. Dudzik¬π, E. Niedzia≈Çkowska¬π, P. Nowak¬π, A. Hogendorf¬≤¬≥, A. Michalak-Zym¬π, D. B. Napruszewska¬π, A. Jarzƒôbski‚Å¥‚Åµ, K. Szyma≈Ñska‚Å¥, W. Bia≈Ças‚Å∂, M. Szaleniec¬π‚úâ**

Received: 14 April 2016 / Revised: 25 August 2016 / Accepted: 20 September 2016 / Published online: 11 October 2016  
¬© Springer-Verlag Berlin Heidelberg 2016

### Abstract
Steroid C25 dehydrogenase (S25DH) from *Sterolibacterium denitrificans* Chol-1S is a molybdenum oxido-reductase belonging to the so-called ethylbenzene dehydrogenase (EBDH)-like subclass of DMSO reductases capable of the regioselective hydroxylation of cholesterol or cholecalciferol to 25-hydroxy products. Both products are important biologically active molecules: 25-hydroxycholesterol is responsible for a complex regulatory function in the immunological system, while 25-hydroxycholecalciferol (calcifediol) is the activated form of vitamin D‚ÇÉ, used in the treatment of rickets and other calcium disorders. Studies revealed that the optimal enzymatic synthesis proceeds in fed-batch reactors under anaerobic conditions, with 6‚Äì9 % (w/v) 2-hydroxypropyl-Œ≤-cyclodextrin as a solubilizer and 1.25‚Äì5 % (v/v) 2-methyloxyethanol as an organic co-solvent, both adjusted to the substrate type, and 8‚Äì15 mM K‚ÇÉ[Fe(CN)‚ÇÜ] as an electron acceptor. Such thorough optimization of the reaction conditions resulted in high product concentrations: 0.8 g/L for 25-hydroxycholesterol, 1.4 g/L for calcifediol and 2.2 g/L for 25-hydroxy-3-ketosterols. Although the purification protocol yields approximately 2.3 mg of pure S25DH from 30 g of wet cell mass (specific activity of 14 nmol min‚Åª¬π mg‚Åª¬π), the non-purified crude extract or enzyme preparation can be readily used for the regioselective hydroxylation of both cholesterol and cholecalciferol. On the other hand, pure S25DH can be efficiently immobilized either on powder or a monolithic silica support functionalized with an organic linker providing NH‚ÇÇ groups for enzyme covalent binding. Although such immobilization reduced the enzyme initial activity to less than twofold it extended S25DH catalytic lifetime under working conditions at least 3.5 times.

**Keywords** Calcifediol ¬∑ 25-hydroxycholesterol ¬∑ Regioselective hydroxylation ¬∑ Sterol ¬∑ Steroid C25 dehydrogenase ¬∑ Molybdenum enzyme

### Introduction
Sterols are ubiquitous compounds in nature that play a range of physiological roles in all living organisms. In mammals, they are mostly used as cell membrane components, hormones, and vitamin D precursors, which leads to their wide application as pharmaceuticals. Therefore, the ability to modify their base structure and to introduce functional groups is of the utmost importance. Although traditional methods of organic chemistry in the synthesis of many steroid drugs have been successfully used with great efficiency, biocatalytic methods (being more selective and environmentally friendly) have recently attracted more attention and have been incorporated into the organic synthesis.

chemists‚Äô toolbox (Brixius-Anderko et al. 2015; Donova 2007; Holland 1992; Riva 1991; Zhang et al. 2014).

25-hydroxylated derivatives of sterols play an important role in human metabolic control and treatment of associated disorders. 25-hydroxycholesterol (25-OH-Ch) is known to perform a complex regulatory function in the immunological system by (i) controlling the differentiation of monocytes into macrophages, (ii) suppressing the production of IgA by B cells, and (iii) directing the migration of activated B cells to the germinal follicle (Bauman et al. 2009; McDonald and Russell 2010; Reboldi et al. 2014). Thus, 25-OH-Ch is proposed as a drug in diseases associated with IgA overproduction such as Berger disease (Bauman et al. 2009). Calcifediol (25-OH-D\(_3\)) is an activated form of cholecalciferol (vitamin D\(_3\)), an important compound introduced into the organism from dietary sources or formed in skin tissue from 7-dehydrocholesterol after sunlight UV irradiation and further activation (epidermolytic hydroxylation) in liver (Zhu et al. 2013). 25-OH-D\(_3\) is the main blood-circulating metabolite responsible for maintaining calcium and phosphate homeostasis. As a drug, calcifediol is much more potent than the parental vitamin D\(_3\) and therefore is used in the treatment of rickets and other calcium disorders (Bischoff-Ferrari et al. 2012; Brandi and Minisola 2013; Jetter et al. 2014).

However, the production of sterols derivatives activated at C25 is not a well-established process in industrial and medical applications (McDonald and Russell 2010). The chemical syntheses of both compounds require a multi-step approach which poses high time and labor demands on the production and results in relatively low yields of the overall synthetic pathways (6‚Äì25 %) (Kurek-Tyrlik et al. 2005; Miyamoto et al. 1986; Ogawa et al. 2009; Riediker and Schwartz 1981; Ryzner at al. 2002; Westhover and Covey 2006). The more efficient method of 25-OH-Ch synthesis (yield 60‚Äì70 %) requires an expensive starting material such as desmosterol (Zhao et al. 2014). On the other hand, the reported enzymatic methods are much more straightforward and usually involve single hydroxylation step catalyzed by P450 cytochromes (Ban et al. 2014; Yasuda et al. 2013; Yasutake et al. 2013) or a non-heme monooxygenase overproduced in transgenic plants Arabidopsis thaliana and Solanum tuberosum (Beste et al. 2011).

**Steroid C25 dehydrogenase (S25DH)** from Œ≤-proteobacterium *Sterolibacterium denitrificans* (Chol-1S), a facultative anaerobic microorganism capable of the full mineralization of cholesterol in both aerobic and anaerobic conditions (Tarlera 2003) appears to be another example of a catalyst for the regioselective hydroxylation of sterols and their derivatives. S25DH is a molybdenum enzyme belonging to the so-called ethylbenzene dehydrogenase (EBDH)-like subclass of DMSO reductases (Heider et al. 2016; Hille et al. 2014). It is a heterotrimer (Œ±Œ≤Œ≥\(_2\), 168 ¬± 12 kDa) containing a bis-pyranopterin-guanine dinucleotides (MGD)-molybdenum cofactor and [4Fe-4S] cluster in the Œ± subunit (105 kDa), four more iron-sulfur clusters in the Œ≤ subunit (38 kDa) and a heme in the Œ≥ subunit (27 kDa) (Demmer and Fuchs 2012).

In the cholesterol degradation pathway, S25DH activates a tertiary C25 carbon atom of the cholest-4-en-3-one by introduction of the oxygen atom that originates from a water molecule, finally yielding the 25-hydroxycholest-4-en-3-one (Glenn et al. 2007, 2008b) (Fig. 1a). Beside its native substrate, S25DH also catalyzes the regioselective hydroxylation of other 3-ketosterols, 3-hydroxyesterols (e.g., cholestanol and 7-dehydrocholesterol) and cholecalciferol (Demmer and Fuchs 2012; Warnke et al. 2016) (Fig. 1b). Therefore, the enzyme can be applied in the catalytic synthesis of pharmacologically important molecules such as 25-hydroxycholesterol, 25-hydroxy-7-dehydrodesofolstrol (hydroxylated pro-vitamin D\(_3\), 25-OH-pro-D\(_3\)), and calcifediol (25-OH-D\(_3\)) (Demmer and Fuchs 2012; Szaleniec et al. 2015; Warnke et al. 2016).

In this work, we present extensive studies on the engineering of reaction medium, the optimization of the biocatalyst formulation and the simplified aerobic purification procedure of steroid C25 dehydrogenase from *S. denitrificans*. To apply S25DH for hydroxylation of sterols, cholecalciferol, or ergocalciferol (Fig. 1b), the following obstacles had to be overcome: (i) the low solubility of hydrophobic reagents in aqueous medium, (ii) the sensitivity of S25DH to oxygen, (iii) the low stability of the enzyme in pure organic solvents, (iv) the oxidation of main aldoketones, such as hydrocortisone, into 3-ketosterols (such as cholest-4-en-3-one), and (v) the limitation of the reaction conversion by the availability of enzyme re-oxidant. Here, we provide the results of a stepwise optimization of the reaction conditions that addresses these issues. Moreover, to demonstrate a real application potential of S25DH, we conducted the syntheses of 25-OH-Ch and 25-OH-D\(_3\) in fed-batch reactors using either pure enzyme or enzyme preparation. The preparations of 25-hydroxy 3-ketosterols were carried out in fed-batch reactors systems using either the homogenous or immobilized enzyme. We also used a plug flow reactor thus broadening the scope of reaction systems and introducing a possibility of switching from a batch process to a continuous one.

## Methods

### Materials and bacterial strain

All chemicals of analytical grade were purchased from Sigma-Aldrich (Poland), Avantor Performance Materials (Poland), GE Healthcare (USA) or Carbosynth Ltd. (UK). Cholest-1,4-dien-3-one was synthesized according to Barton's protocol (Iida et al. 1988) (melting point: 99‚Äì101 ¬∞C, lit. 97‚Äì100 ¬∞C (Czarny et al. 1977)), while cholesteryl succinate Tris salt was prepared according to Bildzikevich‚Äôs protocol

Appl Microbiol Biotechnol (2017) 101:1163‚Äì1174

---

**Fig. 1** Steroid C25 dehydrogenase characterization. a 25-hydroxycholest-4-en-3one synthesis scheme presenting substrate hydroxylation with simultaneous enzyme reduction ($S25DH_{ox}$) and further enzyme re-oxidation ($S25DH_{red}$) by one of the artificial electron acceptors. b S25DH substrates chemical structures divided to 3-ketosterols, 3-hydroxysterols and others.

![Fig. 1 Image](2_0.png)

(Bildzuikevich et al. 2013) (melting point of acid: 174‚Äì176 ¬∞C, lit. 176‚Äì177 ¬∞C (Carvalho et al. 2010)). *S. denitrificans* Chol-1S (DSMZ 13999) was purchased from the Deutsche Sammlung fur Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany).

### Cultivation of bacteria

*Sterolibacterium denitrificans* was grown on cholesterol as a sole carbon source at 30 ¬∞C under anoxic, denitrifying conditions as previously described (Chiang et al. 2008b; Tarlera 2003). Large-scale fermenter cultures (100‚Äì150 L) were conducted according to a previously described procedure (Chiang et al. 2007) with the automatic measurement of pH and supplementation of 1 M sulfuric acid. The fermentations were conducted in the facility of the Department of Biotechnology and Food Microbiology, University of Life Sciences in Poznan, Poland. Cells were harvested by centrifugation during the exponential growth phase at an optical density of 0.8‚Äì1.0 and stored at ‚àí80 ¬∞C.

### Aerobic enzyme purification

The S25DH was purified from *S. denitrificans* according to a modified protocol (Dermer and Fuchs 2012) under aerobic conditions. Briefly, the procedure comprised four steps: (i) cell extract solubilization, (ii) ion-exchange separation on DEAE-Sepharose, (iii) ion-exchange separation on Q-Sepharose, and (iv) affinity separation on Reactive Red 120 (see Table S1).

### Enzyme immobilization

The immobilization of pure S25DH was conducted on four types of support: (i) Granocel and commercial cellulose; (ii) mesostructured cellular foam (MCF, SBA15, and SBA15-ultra (Santa Barbara Amorphous) silica powder carriers with amino groups; (iii) Eupergit¬Æ C; and (iv) silica monoliths with amino groups (see Table S2 for BET surface characterization). Briefly, the immobilization procedure advanced along the following steps: (i) carrier activation (if needed), (ii) rinsing of the activator, (iii) binding of S25DH in the presence of a protective re-oxidant ($K_3[Fe(CN)_6]$), and (iv) end-capping of the still-free active surface groups with Tris. All eluates were collected and analyzed for the presence of the unbound protein and S25DH activity. The amount of protein bound to a carrier was calculated as the difference between the amount of the protein used for the immobilization and the amount of unbound protein. The initial activity of the immobilized biocatalysts was determined in an HPLC assay after the first 3 h of reaction in the batch system. The activity recovery (AR) was calculated as a ratio of the specific activities [mU mg of enzyme] measured for the immobilized and the free enzyme. A description of the carrier syntheses and functionalizations, as well as a detailed description of the

S2SDH activity assay

The standard reaction assay was prepared in a 0.4-mL sample probe containing 280 mM KH‚ÇÇPO‚ÇÑ/K‚ÇÇHPO‚ÇÑ pH 7.0 buffer, 12.5 mM K‚ÇÉ[Fe(CN)‚ÇÜ] as an electron acceptor, 8% (v/v) 2-hydroxypropyl-Œ≤-cyclodextrin (HBC) as a solubilizer, 1.25% (v/v) 2-methoxyethanol (EGME) as an organic co-solvent and substrate stock solution, containing app. 0.25 g/L of sterol substrate (C3-ketone, C3-alcohol, C3-ester, or cholecalciferol) and S2SDH (in an amount differing depending on the substrate type and the purity of the enzyme). The reactions were carried out under anaerobic conditions at 30 ¬∞C in a thermoblock shaker at 800 rpm. As in each reaction cycle two equivalent protons are released to the reaction medium, the elevated concentration of the buffer (i.e., 280 mM) was used in order to maintain a stable pH during the prolonged reaction runs (up to six analyses).

The tests with immobilized S2SDH were conducted at a 10-fold higher scale (4 mL), where 0.5 mL of the immobilized enzyme suspension was used as a catalyst.

UV-Vis detection of activity

The activity was measured spectrophotometrically at 420 nm, 30 ¬∞C in a 0.4-mL sample probe containing 70 mM KH‚ÇÇPO‚ÇÑ/K‚ÇÇHPO‚ÇÑ pH 7.0 buffer and 0.2 mM K‚ÇÉ[Fe(CN)‚ÇÜ] as an electron acceptor. The initial substrate concentration was 0.25 g/L, and the pure enzyme concentration was 0.625 ¬µg/mL. These tests were conducted in triplicate. The assay was used in the optimization of reaction conditions for cholest-4-en-3-one, where the HBC content was tested in the range of 8‚Äì20% (v/v) and EGME in the range of 1.25‚Äì10% (v/v).

HPLC detection of activity

The reagent concentrations in the reactors were monitored over time by the collection of 10-¬µL samples. The reactions were stopped by the addition of the sample to 10 ¬µL of isopropanol and 1 ¬µL of a saturated solution of FeSO‚ÇÑ. The precipitated enzyme and electron acceptor were centrifuged (25,000g, 15 min), and the sample was transferred to a glass vial for LC-MS analysis. Samples were analyzed with RP-HPLC-DAD-MS on an Ascentis¬Æ Express RP-Amide column (2.7 ¬µm, 7.5 cm √ó 4.6 mm, 1 mL/min) using the gradient method 55‚Äì98% acetonitrile/H‚ÇÇO/10 mM NH‚ÇÑCH‚ÇÉCOO (DAD(+)‚ÄìESI-MS) for C3-ketones and cholecalciferol and 95‚Äì98% acetonitrile/H‚ÇÇO/0.01 % HCOOH for C3-alcohols and esters (DAD(+)‚ÄìAPCI-MS). The quantitative analysis was conducted with a DAD detector (240 nm for cholest-4-en-3-one and cholest-1,4-dien-3-one, 265 nm for cholecalciferol and ergocalciferol, 280 nm for 7-dehydrocholesterol, and 205 nm for cholesterol and cholesteryl succinate). The hydroxylation of the product was confirmed by MS spectroscopy (Table S4) by the detection of the characteristic quasi-molecular signals corresponding to the masses of the product [M + H]‚Å∫ or [M + K]‚Å∫ higher by 16 m/z than the respective quasi-molecular signals of the substrate or characteristic of product fragmentation signals (e.g., [M + H ‚àí H‚ÇÇO]‚Å∫).

Reactor systems (batch, fed-batch, plug flow)

Optimization of the reactor conditions for cholecalciferol and cholesterol were carried out under anaerobic conditions in 20 and 2 mL volumes, respectively. The reactor contents comprised the enzyme preparation (15.5 and 1.15 mL, respectively; C‚ÇÅ = 1.0 mg/mL, specific activity (SA) = 1.34 mU/mg) as a catalyst and reaction buffer, 12.5 mM K‚ÇÉ[Fe(CN)‚ÇÜ] and varied amounts of EGME with substrate (1.25‚Äì5% (v/v), substrate stock concentration: 20.2 g/L for cholecalciferol, 12.8 g/L for cholesterol) and HBC (1‚Äì12 % (v/v) for cholecalciferol, or 16% (v/v) for cholesterol). Increased amounts of EGME (1.25, 2.5, and 5% (v/v)) resulted in increased loadings of cholecalciferol (0.25, 0.5, and 1 g/L, respectively) or cholesterol (0.16, 0.32, and 0.64 g/L, respectively).

The 12 different reactions (four tests with replicates) with cholecalciferol were carried out in batch conditions with magnetic stirring bars (500 rpm) at 25‚Äì30 ¬∞C. The 12 different reactions with cholesterol were carried out with shaking at 800 rpm at the same temperature conditions (25‚Äì30 ¬∞C). The average volume activity (VA) for each reactor was calculated from the first 24 or 15.5 h of the reaction cycle (cholesterol or cholecalciferol, respectively) and presented as the 3D contour plots in STATISTICA v10 (StatSoft) using a distance-weighted least squares fitting for non-linear interpolation (Neter et al. 1985).

In fed-batch mode, the substrate and electron acceptor were supplemented by the addition of substrate in EGME (20 g/L stock solution) or K‚ÇÉ[Fe(CN)‚ÇÜ] (1 M stock solution) whenever an HPLC analysis showed a low level of the substrate (<0.05 g/L) or a UV-Vis measurement (Abs 420 nm, $\varepsilon = 1040 \text{ M}^{-1} \text{ cm}^{-1}$) showed a low concentration of the re-oxidant.

Reactors with electrochemical recovery of re-oxidant

The reactions with the electrochemical recovery of the re-oxidant were carried out in anaerobic conditions in batch reactors fitted with an electrochemical system, as previously described (Tataruch et al. 2014).

Plug flow reactor

The reactions in 1.5-mL monolithic silica plug flow reactors (Szymanska et al. 2013) were conducted in anaerobic conditions using cholest-1,4-dien-3-one (0.23 g/L) as a substrate in

280 mM buffer K‚ÇÇHPO‚ÇÑ/KH‚ÇÇPO‚ÇÑ, pH 7.0 containing 8% (w/v) HBC, 1.25% (v/v) EGME, and 12.5 mM K‚ÇÉ[Fe(CN)‚ÇÜ]. Next, 10 mL of the reaction mixture was pumped through the reactor at a 0.1 mL/min flow rate. The reagent concentrations were determined by HPLC at the end of the reactor. After each pass through the reactor, the reaction mixture was collected for the next pass. Altogether, the reactor was tested across 7 days time with six passages of the reaction mixture.

### Product separation

The reaction mixtures were extracted with ethyl acetate (3 √ó 0.25 of reaction medium volume). The combined extracts were washed with saturated KCl\(_{aq}\), dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The obtained residue was purified using column chromatography on silica with ethyl acetate: hexane (1:1).

### Results

#### Low solubility of hydrophobic substrates in aqueous medium

Despite the presence of solubilizer a small content of organic solvent (at least 1%) for introduction of steroid into the reaction mixture is always required. The previously established S25DH assay was based on 20% (v/v) HBC and 1.25% (v/v) 1,4-dioxane (Dermer and Fuchs 2012). We tested S25DH activity with UV-VIS assay in other organic solvents for compatibility with S25DH such as tert-butanol, 2-propanol, methanol, ethyl 1,2-propandiol and 2-methoxyethanol (ethylene glycol monomethyl ether (EGME)) (data not shown). Above all, EGME proved to be the most efficient substitute of 1,4-dioxane. We determined S25DH initial activity in cholest-4-en-3-one hydroxylation (constant substrate concentration) with different HBC and EGME content (Fig. 2a). Hence, S25DH reaction rate turned out to be dependent on the ester solubility in reaction medium (lower range for HBC/EGME competition) and putative substrate sequestration by the multiple-HBC complexes (Yamamoto et al. 2005) (upper HBC range) together with the detrimental influence of the organic solvent on the enzyme activity (EGME upper range). Notably, in the presence of EGME, the content of HBC could be reduced from 20% (w/v) to 8% (w/v) without cholest-4-en-3-one precipitation from the solution. This, in turn, increased the observed initial S25DH drihydratether conversion rate (achieved with 8% (w/v) HBC and 1.25% (v/v) EGME compared to the assays with 20% (w/v) HBC and 1.25% (v/v) 1,4-dioxane). Thus, 8% HBC and 0.8% (v/v) HBC and EGME was identified as the most favorable for hydroxylation of cholest-4-en-3-one, although the enzyme tolerated EGME levels up to 0.5% (v/v).

Subsequently, the selected optimal medium conditions utilizing EGME was compared to previously described conditions utilizing 1,4-dioxane in the experiment employing two parallel reactors with the same enzyme and initial cholest-4-en-3-one concentrations (Fig. 2b). Again, the change of solubilizer content and organic co-solvent type resulted in a significantly higher conversion rate after 4 h of reaction, i.e., 31% for reactor with EGME and 18% for reactor with 1,4-dioxane. Moreover, a better dissolution of the substrate was achieved in reactor with EGME (respectively, 0.3 and 0.25 g/L), despite the same substrate concentration in the organic stock solutions.

As the substrates of interest differ in hydrophobicity (log P for cholesterol 8.7, cholest-4-en-3-one 8.4 and cholecalciferol 7.9 ‚Äì XLogP, PubChem DataBase), the HBC and EGME content in the S25DH reaction mixture were optimized individually for each substrate. Furthermore, as the reported apparent $K_m$ values for S25DH are relatively high (in the range of 0.4‚Äì0.8 mM) (Warnke et al. 2016), the increased substrate loading of the reactors has a significant impact on the observed reaction rate. Therefore, the increased EGME content was combined with the increase of substrate concentration. The optimal reaction conditions were determined using the average volume activity (VA) from the first 24 or 15.5 h of cholesterol or cholecalciferol hydroxylation in batch reactors.

5_0.png

Fig. 2 Reaction medium optimization for cholesterol-4-en-3-one. a Initial volume activity $VA_{\text{init}}$ of S25DH as a function of HBC and EGME contents. In all tests, the substrate concentration was 0.25 g/L. b Progress curves for cholesterol-4-en-3-one (squares) to 25-OH-product (circles) conversions for reaction mixture with 1.25 % (v/v) 1,4-dioxane (black, solid line) and EGME (blue, dashed line). In both experiments, the other conditions, including the amount of S25DH enzyme (SA 15 mU/mg), were identical

For cholecalciferol (Fig. 3a), the optimum reaction medium conditions were found to be 6‚Äì8 % (w/v) HBC and 5 % (v/v) EGME while for cholesterol (Fig. 3b): 6‚Äì9 % (w/v) HBC and 2.5 % (v/v) EGME. Initial substrate concentrations reached 0.52 g/L for cholecalciferol and 0.32 g/L for cholesterol, respectively.

Aerobic vs. anaerobic atmosphere 

The enzymes of the EBDH class, including S25DH, were reported to be oxygen sensitive, especially in their reduced state (Dermer and Fuchs 2012; Szaleniec et al. 2007; Tataruch et al. 2014). Despite some contradicting reports (Wamke et al. 2016), we decided to assess the influence of an oxygen-containing atmosphere on the long-term performance of the S25DH catalyst. Two 8-mL batch reactors were prepared for the hydroxylation of 7-dehydrocholesterol: one under aerobic conditions and the other in a glove box (97 % $N_2/3$ % $H_2$) (Fig. 4, Fig. S3). The final product concentration in aerobic reactor reached 0.05 g/L and the enzyme was inactivated (no further change in product concentration) after approximately 48 h. Meanwhile, under anaerobic conditions, 0.15 g/L of product was reached, and the enzyme remained active for at least 150 h. A similar effect was observed for the immobilized S25DH [Fig. 4 circles), where at an initial period of an identical reaction rate (app. 24 h), the enzyme working under aerobic atmosphere lost most of its activity within 96 h, while the enzyme under anaerobic atmosphere remained active after 480 h of continuous processing. It should be underlined that in each case, the reaction progress was not limited by substrate availability, as the initial concentration of 7-dehydrocholesterol was in the range of 0.29‚Äì0.36 g/L (Fig. S3 of Supplementary Material), and the $K_3[Fe(CN)_6]$ was replenished whenever it reached a low level.

5_1.png

Fig. 3 Volume activity (VA) of S25DH in batch reactor tests with a cholecalciferol and b cholesterol as a function of the HBC and EGME content. As the substrates were dissolved in EGME, higher substrate loadings were obtained for higher EGME contents

![](5_0.png)

![](5_1.png)

6_0.png

![6_0.png](6_0.png)

---

**Fig. 4** Influence of oxygen-containing atmosphere on S25DH activity. Progress curves of 7-dehydrocholesterol conversions conducted in aerobic (filled symbols) and anaerobic (empty symbols) conditions for homogeneous (squares, solid black line SA 0.5 mU/mg) and immobilized (SBA15-AEPA15) pure enzyme (blue circles, dashed line SA 0.1 mU/mg) 

---

**Table 1** Results of batch reactor conversion of S25DH substrates in reaction mixture containing 8 % (w/v) HBC and 1.25 % (v/v) EGME

| Substrate               | VA [mU mL‚Åª¬π] | ùë™‚Å∞ [g L‚Åª¬π] | Product ùë™ùíá‚Å±‚Åø [g L‚Åª¬π] | Time to 90 % conversion [h] | Total reaction time [days] |
|-------------------------|--------------|------------|---------------------------|-----------------------------|----------------------------|
| Cholest-4-en-3-one      | 1.18         | 0.28       | 0.28                      | 4                           | 1                          |
| Cholest-1,4-dien-3-one  | 1.18         | 0.25       | 0.25                      | 4                           | 1                          |
| Choelcalciferol         | 3.15         | 0.3        | 0.3                       | 46                          | 5                          |
| 7-dehydrocholesterol    | 3.15         | 0.34       | 0.19                      | ‚Äî                           | ‚Äî                          |
| Ergocalciferol          | 3.15         | 0.25       | 0.0012                    | ‚Äî                           | ‚Äî                          |
| Cholesterol             | 6.3          | 0.34       | 0.23                      | ‚Äî                           | ‚Äî                          |
| Cholesteryl succinate   | 6.3          | 0.92       | 0.506                     | ‚Äî                           | 19                         |

Total enzyme amount of pure enzyme introduced into reactor, ùë™‚Å∞ initial substrate concentration, ùë™ùíá‚Å±‚Åø final product concentration, time to 90 % conversion time in which 90 % of substrate was converted to product, Total reaction time time at which final product concentration was reached

allowed a much higher loading of the batch reactor (0.92 g/L instead of 0.26 g/L), which resulted in a high yield of the product (0.5 g/L), the reaction proceeded significantly slower than in the case of cholesterol (Table 1, Fig. S6, of Supplementary Material). The identity of S25DH products was confirmed by LC-MS and NMR (Table S4, Fig. S10‚Äì13 of Supplementary Material) and was consistent with that to reported before (Chiang et al. 2007; Warnke et al. 2016).

## Electrochemical recovery of S25DH re-oxidant

During the reaction, S25DH is reduced by a sterol substrate and then re-oxidized by an artificial electron acceptor ($\text{K}_3[\text{Fe(CN)}_6]$ or [Fe(cp)2]BF4). The preliminary tests with [Fe(cp)2]BF4 indicated its interaction with a substrate solubilizer, HBC. This phenomenon was confirmed by cyclic voltammetry experiments, which showed a gradual shift of the ferrocenium potential in the HBC solution toward more positive value and a decrease of the observed current (data not shown). As no such effect was observed for $\text{K}_3[\text{Fe(CN)}_6]$, it was used in the subsequent tests. The reactor experiments revealed efficient substrate hydroxylation in a broad range of $\text{K}_3[\text{Fe(CN)}_6]$ concentrations (1‚Äì15 mM). However, an increase of the re-oxidant concentration above 10 mM had a detrimental effect on the S25DH activity.

Despite the observed interaction with $\text{K}_3[\text{Fe(CN)}_6]$, we employed an electrochemical reactor (Fig. 5) with cholesterol as a substrate and crude enzyme as catalyst, i.e., a low-cost catalyst, that due to the side reactions with other redox proteins, consumes more re-oxidant. Initially, at sustained high concentration of $\text{K}_3[\text{Fe(CN)}_6]$, the conversion in the electrochemical reactor proceeded faster than in the control reactor without electrochemical recovery. However, after approximately 48 h, the hydroxylation rate in the electrochemical reactor decreased, and the enzyme had become inactive after 100 h. Meanwhile, the enzyme in the control reactor was able to catalyze the hydroxylation of cholesterol for 70 h, despite the gradual loss of its activity. A similar effect was observed for pure enzyme hydroxylating cholest-4-en-3-one, as well as for the hydroxylation of ethylbenzene by immobilized EBDH (data not shown).

## Immobilization of S25DH

The activity of immobilized enzyme preparations was evaluated for different supports in batch reactors with cholest-1,4-dien-3-one as a substrate (Table 2). As a reference, homogeneous S25DH with an initial activity corresponding to that used for preparation of the immobilized catalyst (8.04 mU) was used. In each case, 0.5 mL of the settled immobilized catalyst was suspended in 3.5 mL of the reaction mixture and placed in a thermostated reactor at 30 ¬∞C in an anaerobic atmosphere. The reaction progress was monitored by HPLC for 2 weeks (Fig. S9 of Supplementary Material). The highest activity recovery (% of immobilized specific activity, AR) was observed for mesostructured cellular foam (MCF) and Santa Barbara Amorphous (SBA-15) silica supports both functionalized with 2-aminoethyl-3-aminopropyltrimethoxysilane (AEAPTS; 45 and 30 %, followed by SBA-units grafted with 3-(2-aminoethylamino)propyldiethoxysilane (AEAPDES; 34 and 18%). The lowest ARs were detected for S25DH immobilized on cellulose carriers (1‚Äì2 %) and Eupergit¬Æ C (0.3 %). In order to test the influence of the functionalization linker, further experiments were conducted employing AEAPTS or APETS as linkers on SBA-ultima carriers with pure enzyme (SA 4.67 mU/mg) (Table S3 Supplementary Material). For both carriers functionalized by a longer (AEAPTS) or a shorter (APTES) linker, similar values of protein loading as well as initial activity and AR were obtained. Thus, under experimental conditions the influence of the linker was not observed.

## S25DH hydroxylation applications

**Synthesis of 25-OH-Ch** The synthesis of 25-OH-Ch in a fed-batch reactor (25 ¬∞C, 8 % (v/v) HBC; 1.25‚Äì3.75 % (v/v) EGME; 0.12 mL of pure enzyme SA 14 mU/mg, anaerobic atmosphere) resulted in an app. 0.8 g/L product concentration after 500 h of reaction (Fig. S6 of Supplementary Material) and conversion of 40‚Äì60 %. The conversion and subsequent downstream processing can be further optimized by decreasing the substrate addition at the later stage of the reaction.

**Synthesis of 25-OH-D3** The synthesis of 25-OH-D3 in a fed-batch reactor was carried out in two parallel 20-mL glass reactors (25 ¬∞C, 8 % (v/v) HBC and 5 % (v/v) EGME, initial

![7_0.png](attachment://7_0.png)

### Fig. 5 Influence of electrochemical recovery of $\text{K}_3[\text{Fe(CN)}_6]$ on S25DH activity (crude enzyme, SA = 0.39 mU/mg); progress curves for cholesterol (filled squares) to 25-OH-Ch (empty circles) conversions conducted with (blue, dashed line) and without electrochemical recovery (black, solid line)

Table 2 Catalytic characterization of immobilized 5$2\beta$DH in reaction with cholest-1,4-dien-3-one. The reference activity of homogenous 5$2\beta$DH tested with cholest-1,4-dien-3-one was 20.1 mU/mL ($SA$ 6.6 mU/mg)

| Carrier                    | Bound protein [mg/g] | Protein loading [mg/mL] | Initial activity [mU/mL] | Activity recovery [\%] | $c^{prod}$ 14th day [g/L] |
|----------------------------|----------------------|-------------------------|-------------------------|----------------------|---------------------------|
| OH-GranoCel                | 1.17 (96)            | 2.34                    | 0.3                     | 2.1                  | 0.034                     |
| Commercial cellulose       | 0.96 (79)            | 1.92                    | 0.1                     | 1.0                  | 0.006                     |
| MCF-AEAPS1                 | 1.21 (99)            | 2.42                    | 7.2                     | 45.1                 | 1.748                     |
| SBA15-AEAPTS               | 1.22 (100)           | 2.44                    | 4.8                     | 29.9                 | 1.670                     |
| SBA15-ultra-1-APTES        | 1.21 (100)           | 2.42                    | 2.0                     | 12.7                 | 0.437                     |
| SBA15-ultra-2-APTMS        | 1.22 (100)           | 2.44                    | 2.2                     | 13.9                 | 0.368                     |
| Eupergit C                 | 0.68 (56)            | 1.36                    | 0.3                     | 0.3                  | 0.229                     |

_MCF_ mesostructured cellular foam, _AEAPTS_ 2-aminoethyl-3-aminopropyltrimethoxysilane, _SBA_ Santa Barbara amorphous, _APTES_ 3-aminopropyltriethoxysilane, _APTMS_ 3-aminopropyltrimethoxysilane

![8_0.png](attachment://8_0.png)

_Fig. 6 Reaction progress curve of the fed-batch synthesis of calcifediol. Filled circles calcifediol, empty squares cholecalciferol_

**Discussion**

_Optimization of reaction conditions_ The low solubility of steroids in aqueous medium is a known problem in their biotransformation that limits the yield of such processes (Rao et al. 2013). However, the reactor loading can be increased by the addition of steroid solubilizers, such as 2-hydroxypropyl-$\beta$-cyclodextrin (HBC) together with organic co-solvent, which additionally enables an easy introduction of the substrate to the reaction medium. Comparative tests of differently functionalized $\beta$-cyclodextrins showed that HBC is especially efficient in the solubilization of sterols, followed by methyl-$\beta$-cyclodextrin. The unmodified $\beta$-cyclodextrin proved to be very inefficient in that process and limited the conversion. A thorough investigation of the influence of HBC on the observed activity showed that both low and too high contents of cyclodextrin were detrimental to the reaction rate. The low HBC content results in the low solubility of the substrate and its subsequent precipitation from the reaction medium. On the other hand, a high content of HBC is most probably associated with substrate sequestration by cyclodextrins forming tubular supramolecular structures. This effectively decreases the substrate concentration available to the enzyme (Decaprio et al. 1992; Williams et al. 1998). As a

Fig. 7 Schematic representation of the optimization of reaction conditions for S25DH presenting how concentrations of sterol solubilizer (HBC) and organic solvent (EGME) influence the S25DH activity and productivity of 25-hydroxyxylsteroids and other sterol derivatives

![](9_0.png)

erythropoiesis cells containing a recombinant vitamin D3 hydroxylase from *Pseudonocardia autotrophica* (Yasutake et al. 2013). In our approach, we were able to reach 1.4 g/L, while experiments with other substrates demonstrated the possibility of going even above 2.0 g/L. The use of isolated enzyme instead of cells also enables the use of less physiological conditions (such as the presence of organic co-solvents) as well as an easy shift from a batch system to flow reactors. In summary, S25DH is an interesting biocatalyst and can be efficiently used in the fine chemical and pharmaceutical industries.

**Acknowledgements** The authors acknowledge the financial support of the Polish institutions of the National Center of Research and Development (grant project: LIDER/037/417/L-5/13/NCBR) and the National Center of Science (grant SONATA UM0-2012/05/D/ST/4/ 00277).

**Compliance with ethical standards**

**Conflict of interest** All authors declare no conflict of interests.

**Human and animal rights and informed consent** This article does not contain studies with human participants or animals performed by any of the authors.

### References

Ban JG, Kim HB, Lee MJ, Anbu P, Kim ES (2014) Identification of a vitamin D3-specific hydroxylase gene through transcriptomics and enzyme mining. J Ind Microbiol Biotechnol 41(2):265‚Äì273. doi:10.1007/s10295-013-1336-9

Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang GS, Russell DW (2009) 25-hydroxycholesterol secreted by macrophages in response to toll-like receptor activation suppresses macrophage lipid accumulation. Proc Natl Acad Sci U S A 106(39):16764‚Äì16769. doi:10.1073/pnas.0904901106

Belete L, Nahar N, Delman K, Fujikota S, Jonsson L, Dutta PC, Sihofen F (2011) Synthesis of hydroxylated sterols in transgenic *Arabidopsis* plants alters growth and sterol metabolism. Planta Physiol 157(1): 426‚Äì440. doi:10.1104/pp.110.171199

Bidluzkiewicz U, Rarova L, Saman D, Hlavicek L, Drasar P, Wimmer Z (2013) Amides derived from heterobacteroate amines and selected steryl menisteres. Steroids 78(14):1347‚Äì1352

Bischof-Ferrari HA, Dawson-Hughes B, St√∂cklin E, Sidelnikov E, Willett WC, Edel JO, St√§helin HB, Wolfram S, Jetter A, Schwager J, Henchskowksi J, von Eckardstein A, Egli A (2012) Oral supplementation effects on 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res 27(1):160‚Äì169. doi:10.1002/ jbmr.551

Brandi ML, Minisola S (2013) Calcidiol (25OHD3): from diagnostic marker to therapeutical agent. Curr Dev Ped Res 289(11):1565‚Äì1572. doi:10.1016/j.maturitas.2013.838549

Br√ºxius-Ando√©e S, S√§nger H, Lannemann F, Janocha B, Bernhardt R (2015) A CYP21A2 based whole-cell system in *Escherichia coli* for the biotechnological production of premurded micro B Enclaficine Calc 14:135. doi:10.1186/s12934-015-0333-2

Campbell JA, Squires DM, Babcock JC (1969) Synthesis of 25-hydroxycholecalciferol biologically effective metabolite of vitamin D3. Steroids 13(5):566‚Äì577

Carvalho JF, Silva MM, Moreira JM, Sinos S, Se a Melo ML (2010) Sterols as anticancer agents: synthesis of ring-B oxygenated steroids, cytotoxic profile, and comprehensive SAR analysis. J Med Chem 53(21):7632‚Äì7638. doi:10.1021/jm101179n

Chiang YR, Ismail W, M√ºller M, Fuchs G (2007) Initial steps in the anoxic metabolism of cholesterol by the denitrifying *Sterolibacterium denitrificans*. J Biol Chem 282(18):13240‚Äì13249. doi:10.1074/bcM.106.190330

Chiang YR, Ismail W, Gallien S, Heintz D, Van Dorsselaer A, Fuchs G (2008a) Cholest-4-en-3-one-delta(1)-dehydrogenase, a flavoprotein catalyzing the second step in anoxic cholesterol metabolism. Appl Environ Microbiol 74(1):107‚Äì113

Chiang YR, Ismail W, Heintz D, Schaffle C, Van Dorsselaer A, Fuchs G (2008b) Study of anoxic acidic cholesterol metabolism by *Sterolibacterium denitrificans*. J Bacteriol 190(3):905‚Äì914. doi:10.1128/jb.01525-07

Czarny MR, Nelson JA, Spence TA (1977) Syntheses of a spiryl Cyclopropenocholestan-3beta-OI. J Org Chem 42(17):2941‚Äì2944. doi:10.1021/jo00437a001

Decaprio J, Jun J, Javitt NB (1992) Bile-acid acid steroid solubilization in 2-hydroxypropyl-Beta-cyclodextrine. J Lipid Res 33(3):441‚Äì443

Demier J, Fuchs G (2012) Molybdenoxybenate that catalyzes the anaerobic hydroxylation of a tertiary carbon atom in the side chain of cholesterol. J Biol Chem 287(44):30965‚Äì30975

DiCosimo R, McAuliffe J, Poulose AJ, Bohlmann G (2013) Industrial use of immobilized enzymes. Chem Soc Rev 42(15):6437‚Äì6474. doi:10.1039/c1353560c

Donova MY (2007) Transformation of sterols by actinobacteria: a review. Process Biochem 82(7):574‚Äì575

Fujii T, Yuki S, Mochido K, Sekine M (1997) A novel cholesterol transforming system in *Escherichia coli* with tac arcB mutations expressing cytochrome P450 genes. Biosci Biotechnol Biochem 73(4): 805‚Äì810. doi:10.1271/bbb.80k8267

Heider J, Szalience M, Stunvoll K, Boll M (2016) Ethylbenzene dehydrogenase and related bodoquinon enzymes involved in oxygen-dependent aliphyl chain hydroxylation. J Mol Microbiol Biotechnol 26(1‚Äì3):45‚Äì62

Hille RA, Baseler H (2014) The monoclonal antibody enyzmes. Chem Rev 114(3):7963‚Äì8038. doi:10.1021/cr400442w

Holland HL (1992) Organic synthesis with oxidactive enzymes. Wiley VCH, New York

Hori E, Shinohara T,Goto J, Nambara T, Cha RC (1988) A facile one-step synthesis of delta-1,4,7-decalic acid esters by iodobenzenze and bromobenzene anhydride. J Lipid Res 29(8):1097‚Äì1101

Kar E, Egli A, Dawson-Hughes B, Stachelin HB, Stoecklin E, Goessler H, Hensachowski J, Bischof-Ferrari HA (2014) Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone 59:14‚Äì19

Kang D-J, Lee H-S, Park T-J, Bang JS, Hong S-K, Kim Y-T (2006) Optimization of culture conditions for the bioconversion of vitamin D3 to 1,25-dihydroxyvitamin D3 using *Pseudonocardia autotrophica* ID 9302. Biotechnol Bioproce E 11(5):408‚Äì413. doi:10.1007/bt9923307

Kang DJ, IM JH, Kang JH, Kim KHJ (2015) Bioconversion of vitamin D3 to calcifleidiol by using resting cells of *Pseudonocardia sp*. Biotechnol Lett 37(9):1895‚Äì1904. doi:10.1007/s10529-015-1862-9

Kurek-Tyrki A, Michalak K, Wicha J (2005) Synthesis of 17-epicalcitriol from a common androsteric derivative, involving the ring B photochemical opening and the introduction of methine triozonolysis. J Org Chem 70(21):8533‚Äì8521. doi:10.1021/jo3517su

McDonald JG, Russell DW (2010) Editorial: 25-hydroxycholesterol: a new life in immunology. J Leukoc Biol 88(6):1071‚Äì1072. doi:10.1189/jlb.0710418

Miyamoto K, Kubode M, Murayama E, Ochi K, Mori T, Matsunaga I (1996) Synthesis of vitamin-D2-14alpha-alcohols. A synthesis of 25-hydroxyverrucosterol from lichen-derived ergosterol. Chem Pharm Bull 44(2):366‚Äì371. doi:10.1248/cpb.44.366

Neter J, Wasserman W, Kutner MH (1985) Applied linear statistical models: regression, analysis of variance, and experimental designs. Irwin, Homewood, IL, USA

Ogawa S, Kakiyama G, Muto A, Hosoda H, Mimura M, Ikegawa S, Hoffman AF, Irda H (2009) A facile synthesis of C-24 and C-25 oxysterols by in situ generated ethylformylimidotrioxirane. Steroids 74(1):81‚Äì87. doi:10.1016/j.steroids.2008.09.015

Rao SM, Thakkar KV, Parikh SJ (2004) Microbial transformation of steroids: current trends in cortical side chain cleavage. Quest 1:16‚Äì20

Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG (2014) 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345(6197): 679‚Äì684. doi:10.1126/science.1254790

R i e d e r e k , S c h w e r t z l e r J ( 1 9 8 1 ) A n e w s y n t h e s i s o f 2 5 - h y d r o x y c h o l e s t e r o l . Tetrahedron Lett 22(46):4655‚Äì4658. doi:10.1016/S0040-4039(01)83057-5

Riva S (1991) Enzymatic modification of steroids, vol 1. Marcel Dekker, Inc., New York

Rynarz T, Krupa M, Kutner A (2002) Synthesis of vitamin D metabolites and analogs. Retrospect and prospects. Pure Chem 81(5):300‚Äì310

Sasaki J, Miyazaki A, Sato M, Adachi T, Mizuke K, Hanada K, Omura S (1992) Transformation of vitamin-D3 to 1-alpha, 25-dihydroxyvitamin-D3 by 25-hydroxyvitamin-D3 using Amycolata sp. strains. Appl Microbiol Biotechnol 38(2):152‚Äì157

Schilke KF, Kelly CJ (2008) Activation of microbial lipases in non-aqueous systems by hydrophobic DL-L-tryptophan interaction. Biotechnol Biopharm 10(1):19‚Äì18. doi:10.1002/abc.2008

Szalieniec M, Hagel C, Menke M, Nowak P, Witko M, Heider J (2007) Kinetics and mechanism of oxygen-independent hydrocarbon hydroxylation by ethylbenzene dehydrogenase. Biochemistry 46(25): 7637‚Äì7646. doi:10.1021/bi700363c

Szalieniec, M, Rugor, A, Dudzik, A, Taturuch, M, Szyma≈Ñska, K, Jarzƒôbski, A (2015) Method of obtaining 25-hydroxylated sterol derivatives, including 25-hydroxy-7-dehydrocholesterol, Poland

Szyma≈Ñska K, Pud≈Ço W, Mrowiec-Bia≈Ço J, Czardybon A, Kocurek J, Jarzƒôbski AB (2013) Immobilization of invertase on silica monoliths with hierarchical pore structure to obtain continuous flow enzymatic microreactors of high performance. Micropor Mesopor Mat 170:75‚Äì82

Tarlera S (2003) Sterolibacterium denitrificans gen. Nov., sp. nov., a novel cholesterol-oxidizing, denitrifying member of the Proteobacteria. Int J Syst Evol Microbiol 53(4):1085‚Äì1091. doi:10.1099/ijs.0.02309-0

Tataruch M, Heider J, Bryjak J, Nowak P, Knack D, Czernƒõ√°k A, Liesene J, Szaleniec M (2014) Suitability of the hydrocarbon-hydroxylating molybdenum-enzyme ethylbenzene dehydrogenase for industrial chiral alcohol production. J Biotechnol 192:400‚Äì409. doi:10.1016 /j.jbiotec.2014.06.021

Warnke M, Jung F, Demmer J, Hippe H, Jehmlich N, von Bergen M, Ferdinand S, Preis A, M√ºller M, Boll M (2016) 25-hydroxyvitamin D3 synthesis by enzymatic steroid side-chain hydroxylation with water. Angew Chem Intl Ed Engl 55(5):1881‚Äì1884. doi:10.1002/ange.201503831

Westover EJ, Covey DF (2006) Derivation of 25-hydroxycholesterol. Steroids 71(6):484‚Äì488. doi:10.1016/j.steroids.2006.01.007

Williams RO, Mahaguna V, Sirovingeajam M (1998) Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin. Eur J Pharm Biopharm 46(3):355‚Äì360. doi:10.1016/S09396411(99)00038-3

Yasuda K, Endo M, Ikushiro S, Kamakura M, Ohta M, Sakaki T (2013) UVD-dependent production of 25-hydroxyvitamin D2 in the recombinant yeast expressing human CYP27B1. Biochem Biophys Res Commun 434(2):311‚Äì315. doi:10.1016/j.bbrc.2013.02.218

Yasutake Y, Nishikota H, Imoto N, Itama Y (2013) A single mutation at the ferredoxin site of Vitamin D3 enables efficient back-end conversion to 25-hydroxycholecalciferol. Appl Microbiol Biotechnol 97:4587‚Äì4597. doi:10.1007/s00253-013-4878-1

Zhu D (2014) Engineering a hydroxysteroid dehydrogenase to improve its soluble expression for the asymmetric reduction of cortisone to 11Œ≤-hydroorcisone. Appl Microbiol Biotechnol 98(21): 8879-8886. doi:10.1007/s00253-014-5967-1

Zhao Q, Ji L, Qian GP, Liu JG, Wang ZQ, WP Y, Chen XZ (2014) Investigation on the synthesis of 25-hydroxycholesterol. Steroids 85:1‚Äì5. doi:10.1016/j.steroids.2014.02.002

Zhu JG, Olschefj; JT, Kaufman M, Jones G, DeLuca HF (2013) CYP27R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A 110(39):15650‚Äì 15655. doi:10.1073/pnas.1315060110

[Springer logo]